Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zidovudine in Early AIDS Related Complex
NCT00001011Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) and AIDS-related complex (ARC) comparing Zidovudine with Placebo (2 arms). Primary endpoints: Ability of AZT to suppress HIV at 104 weeks, Improvement in body defenses at 104 weeks and 2 more. Status: completed.
02
Drugs
zidovudine
03
Conditions
human immunodeficiency virus infection (HIV)AIDS-related complex (ARC)
Beyond the preview
Go deeper on NCT00001011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001011.